List of Excipients in Branded Drug EPTIFIBATIDE

Generic Drugs Containing EPTIFIBATIDE

Company	Ingredient	NDC	Excipient
Baxter Healthcare Company	eptifibatide	0338-9558	CITRIC ACID MONOHYDRATE
Baxter Healthcare Company	eptifibatide	0338-9558	SODIUM HYDROXIDE
Baxter Healthcare Company	eptifibatide	0338-9558	WATER
Hainan Poly Pharm Co Ltd	eptifibatide	14335-070	CITRIC ACID MONOHYDRATE
Hainan Poly Pharm Co Ltd	eptifibatide	14335-070	SODIUM HYDROXIDE
Accord Healthcare Inc	eptifibatide	16729-260	CITRIC ACID MONOHYDRATE
Accord Healthcare Inc	eptifibatide	16729-260	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in EPTIFIBATIDE?

# Of NDCs	Excipient
18	CITRIC ACID MONOHYDRATE
17	SODIUM HYDROXIDE
7	WATER

Last updated: August 9, 2026

ecutive summary: Eptifibatide is a mature intravenous antiplatelet drug with limited conventional patent protection and low excipient complexity. The main commercial opportunities are generic sterile injectable supply, ready-to-use premixed infusion bags, dual-strength hospital products, and manufacturing services rather than novel excipient claims. The formulation uses eptifibatide, citric acid, sodium hydroxide for pH adjustment, and water for injection. Product differentiation depends on supply reliability, container-closure performance, pharmacy workflow, and procurement economics.

Eptifibatide Excipient Strategy and Commercial Opportunities

What is the current formulation of eptifibatide?

Eptifibatide is a cyclic heptapeptide glycoprotein IIb/IIIa inhibitor marketed originally as Integrilin. It is administered intravenously during percutaneous coronary intervention and in patients with acute coronary syndromes. The product is supplied as an injection or infusion solution rather than a tablet, depot formulation, or biologic.

The principal commercial formulations are:

Product strength	Typical use	Core excipients
0.75 mg/mL	Continuous infusion	Citric acid monohydrate, sodium hydroxide, water for injection
2 mg/mL	Intravenous bolus	Citric acid monohydrate, sodium hydroxide, water for injection

The product is an aqueous, sterile, preservative-free formulation. Citric acid provides buffering capacity, while sodium hydroxide adjusts pH. Water for injection is the vehicle. The FDA labeling does not identify a surfactant, antimicrobial preservative, tonicity agent, or complex carbohydrate as a functional excipient in the finished product [1].

This simplicity reduces formulation-development risk but also limits the opportunity to create differentiated intellectual property around the excipient system.

What excipients protect eptifibatide formulations?

The principal formulation-related protection is likely to arise from process controls, container closure, stability data, and sterile manufacturing rather than from a proprietary excipient combination.

Citric acid monohydrate

Citric acid monohydrate is the principal buffering excipient. It helps maintain the solution within the required pH range and can affect peptide stability, oxidation behavior, and compatibility with the container closure system.

For a generic manufacturer, critical controls include:

• Buffer concentration and pH drift over shelf life.
• Interaction between the acidic formulation and elastomeric stoppers.
• Potential metal-ion catalysis of peptide degradation.
• Particulate formation after terminal sterilization or prolonged storage.
• Compatibility with infusion lines and hospital dilution fluids.

A formulation developer should avoid unnecessary buffer changes. Changing the acid system from citric acid to phosphate, acetate, or another buffer may create a regulatory bridge problem because it can alter peptide stability, osmolality, impurity profiles, and container compatibility.

Sodium hydroxide

Sodium hydroxide is used for pH adjustment rather than as a principal buffering component. Its quantity may vary with the manufacturing process and raw-material lot characteristics. The final product specification should control pH, assay, degradation products, and osmolality rather than relying only on the theoretical sodium hydroxide amount.

Water for injection

Water for injection is the aqueous vehicle. Since the drug is administered intravenously, control of bacterial endotoxins, bioburden, particulate matter, and sterility is central to product quality.

Excipients that are not currently central to the reference formulation

The reference formulation does not depend on:

• Benzyl alcohol or another antimicrobial preservative.
• Polysorbate or other surfactant.
• Mannitol or another bulk tonicity agent.
• EDTA or another chelator.
• Albumin or protein stabilizer.
• Lyophilization bulking agents.

Introducing these materials could increase extractables and leachables, compatibility, toxicological, and regulatory burdens without creating a clear clinical advantage.

How should manufacturers design an eptifibatide excipient strategy?

The preferred strategy is formulation conservatism combined with manufacturing differentiation. A generic product should generally preserve the reference product’s qualitative excipient profile unless a specific stability or supply issue justifies change.

Recommended development priorities

Development issue	Commercial relevance	Preferred approach
Peptide stability	Controls shelf life and impurity burden	Optimize pH, oxygen exposure, temperature, and hold times
Container closure	Affects sterility and leachables	Screen glass, elastomers, and bag materials early
Particulates	Can cause injectable-product rejection	Use low-shedding components and validated filtration
Infusion compatibility	Determines hospital usability	Confirm compatibility with saline, dextrose, tubing, and pumps
Supply continuity	Important in hospital tenders	Qualify multiple suppliers for citric acid and packaging
Manufacturing throughput	Drives gross margin	Use high-yield sterile filling and automated inspection
Product differentiation	Supports procurement wins	Offer ready-to-use bags, vial sizes, and reliable allocation

The drug is a peptide, so degradation control deserves greater attention than the small excipient list might suggest. Potential pathways include hydrolysis, oxidation, aggregation, adsorption, and formation of process-related impurities. The final control strategy should include peptide-related substances, visible and subvisible particles, pH, osmolality, sterility, endotoxins, and container-closure integrity.

What formulations are commercially attractive for eptifibatide?

The strongest opportunities are dosage-form and workflow improvements rather than new excipient chemistry.

Ready-to-use infusion bags

A ready-to-use 0.75 mg/mL infusion bag could reduce pharmacy compounding, preparation errors, and nursing workload. It may also improve product consistency in catheterization laboratories and emergency departments.

A premix product should address:

• Bag material compatibility.
• Drug adsorption to the bag or tubing.
• Stability after removal from secondary packaging.
• Overfill specifications.
• Pump accuracy.
• Shipping vibration and temperature excursions.
• Compatibility with common infusion sets.

The main barrier is the relatively concentrated hospital procurement environment. A premix can command a commercial advantage only if the price premium is lower than the labor, waste, and error-avoidance value perceived by the hospital.

Dual-strength hospital portfolio

A two-product portfolio remains commercially logical:

• A concentrated 2 mg/mL product for bolus administration.
• A 0.75 mg/mL product for continuous infusion.

Maintaining both strengths reduces bedside calculations and supports protocol-based use. Packaging should distinguish the two concentrations through label design, cap color, carton configuration, and barcode controls, subject to applicable FDA requirements.

Small-volume vials

Small-volume vials can support bolus use and reduce partial-container waste. The value proposition is strongest in hospitals with intermittent demand or where infusion bags are not routinely stocked.

Prefilled syringes

A prefilled syringe could simplify bolus administration but would face more demanding container-closure, device, dose-accuracy, and human-factors requirements. It may be commercially useful in high-volume catheterization laboratories but is less likely to be the lowest-cost generic option.

Lyophilized eptifibatide

A lyophilized product would require a new excipient system and reconstitution workflow. It could improve long-term stability in selected distribution channels, but it would add manufacturing steps, reconstitution errors, and regulatory complexity. The business case is weak unless the liquid product has an unresolved stability or supply problem.

When did eptifibatide lose exclusivity?

Eptifibatide has lost the commercial protections associated with its original brand launch. Integrilin received FDA approval in 1998, and the principal U.S. patent and regulatory exclusivity periods have expired. The FDA Orange Book does not present eptifibatide as a product protected by an active, commercially material patent barrier comparable to newer specialty medicines [2].

The relevant commercial implication is that competition is primarily governed by:

• ANDA approval timing.
• Sterile manufacturing capacity.
• Hospital contracting.
• Shortage risk.
• Product availability.
• Price and rebate structure.

Eptifibatide is not a biosimilar product. It is a chemically defined peptide drug regulated through the small-molecule drug framework, although its peptide structure creates manufacturing and analytical challenges beyond those of a conventional low-molecular-weight compound.

What is the Orange Book status of eptifibatide?

The Orange Book is the principal U.S. source for listed drug products, therapeutic equivalence evaluations, and patent or exclusivity information. Eptifibatide products are eligible for generic competition through abbreviated new drug applications where the applicant can demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with quality and manufacturing requirements [2].

For an eptifibatide applicant, the relevant regulatory questions are:

1. Is the reference listed drug correctly identified?
2. Does the proposed product match the reference strength, route, dosage form, and qualitative formulation requirements?
3. Are any patent certifications required for listed patents?
4. Does the applicant need a suitability petition or another regulatory pathway?
5. Can the applicant demonstrate injectable-product quality and stability?

Because eptifibatide is administered intravenously, conventional pharmacokinetic bioequivalence may not carry the same role as it does for an oral tablet. The regulatory submission still must address pharmaceutical equivalence, product quality, analytical comparability, and the applicable FDA requirements for injectable solutions.

Which companies are challenging or supplying eptifibatide?

The U.S. market has historically included the original Integrilin product and generic injectable suppliers. Generic participation has included manufacturers and specialty injectable companies such as Hospira, Teva, Sandoz, and other approved or contract-manufactured suppliers, although current commercial availability can vary by presentation and year.

The competitive landscape is fragmented by:

• Vial versus infusion-bag presentation.
• 0.75 mg/mL versus 2 mg/mL strength.
• Direct hospital contracting versus distributor supply.
• Domestic versus offshore sterile manufacturing.
• Shortage-driven procurement.
• Private-label and contract-manufacturing arrangements.

A company entering the market should evaluate active FDA product listings and current wholesaler availability rather than assuming that historical approval equals continuous commercial supply.

What generic entry risks exist for eptifibatide?

The key risks are operational rather than patent-driven.

Sterile manufacturing risk

Eptifibatide requires aseptic processing, validated sterilizing filtration where applicable, environmental monitoring, container-closure integrity testing, and robust particulate control. A single manufacturing deviation can interrupt hospital supply and trigger regulatory action.

Peptide impurity risk

The active ingredient is a cyclic peptide with a disulfide bond. Raw-material consistency, peptide purity, oxidation control, and impurity characterization are critical. A low-cost active pharmaceutical ingredient supplier may create higher downstream testing and release costs.

Container-closure risk

An acidic peptide solution can interact with elastomeric components, glass surfaces, plastic bags, or administration sets. Extractables and leachables can become a regulatory issue even when the excipient list is simple.

Shortage and allocation risk

Hospitals often maintain limited inventories of injectable antiplatelet drugs. A supplier that cannot maintain continuity may lose formulary position quickly. Dual-site manufacturing, redundant component qualification, and adequate safety stock can be more valuable than a marginally lower manufacturing cost.

Labeling and medication-error risk

The two concentrations create a risk of bolus-infusion confusion. Packaging, barcode data, and carton separation are commercial and patient-safety factors. A product with a clear presentation can gain preference in institutional tenders even without a formulation patent.

What patent protection covers eptifibatide formulations?

The original eptifibatide patent estate covered the compound and related pharmaceutical uses. Those rights are now expired or commercially exhausted in the United States. Current opportunity is therefore unlikely to come from blocking patents on the active ingredient.

Potentially protectable improvements could include:

• A specific premixed infusion-bag formulation.
• A validated low-adsorption container system.
• A stability-enhancing oxygen-control process.
• A device-enabled prefilled bolus presentation.
• A manufacturing process that materially improves impurity control.
• A packaging configuration that reduces medication errors.

These claims would need to provide a genuine technical contribution. A patent covering only the use of citric acid, sodium hydroxide, and water for injection in an otherwise conventional eptifibatide solution would face substantial validity and obviousness challenges.

The strongest IP strategy is more likely to involve a combined formulation, container, process, and device claim set than a standalone excipient claim.

Is there Paragraph IV litigation or settlement activity?

Eptifibatide is not associated with a current, high-value Paragraph IV litigation environment comparable to active branded anticoagulants or specialty injectables. Its patent estate is mature, and the principal commercial barriers are regulatory execution and market access.

Potential applicants should still review FDA patent listings and Abbreviated New Drug Application litigation records before filing. A Paragraph IV strategy would have limited economic value unless an unexpired listed patent materially affects a specific presentation or method of use.

No current settlement structure appears to define the U.S. eptifibatide market. The absence of a major settlement-driven launch schedule increases the importance of manufacturing readiness and contracting strategy.

How does eptifibatide compare with competing antiplatelet drugs?

Drug	Route	Main commercial form	Patent position	Excipient opportunity
Eptifibatide	IV	Aqueous bolus and infusion	Mature, largely expired	Premix, packaging, supply reliability
Tirofiban	IV	Aqueous injection	Mature generic market	Similar sterile-injectable opportunity
Abciximab	IV	Monoclonal antibody fragment	Biologic manufacturing complexity	Limited excipient differentiation
Clopidogrel	Oral	Tablet	Generic and highly price competitive	Solid-dose formulation and manufacturing
Ticagrelor	Oral	Tablet	More recent branded/generic transition	Solid-dose and lifecycle management

Eptifibatide competes clinically with other antiplatelet agents, but its intravenous route creates a narrower commercial market. The product is used in acute hospital settings, where availability and protocol fit matter more than consumer brand recognition.

What is the FDA regulatory status of eptifibatide?

The FDA-approved reference product is an intravenous injection used in acute coronary syndromes and percutaneous coronary intervention. Labeling includes weight-based bolus and infusion dosing, with renal-dose considerations for patients with reduced creatinine clearance [1].

For a generic or reformulated product, the regulatory package should focus on:

• Active ingredient identity and peptide purity.
• Sterility and bacterial endotoxin limits.
• Particulate matter.
• Assay and degradation products.
• pH and osmolality.
• Container-closure integrity.
• In-use and dilution stability.
• Compatibility with labeled infusion solutions.
• Stability under shipping and storage conditions.

A premix or device presentation may introduce additional FDA review issues beyond the basic injectable solution, including drug-device compatibility, human factors, and packaging configuration.

What is the commercial opportunity for eptifibatide excipients?

The excipient market opportunity is modest when measured as excipient sales alone. Citric acid, sodium hydroxide, and water for injection are commodity inputs. The larger opportunity is to supply integrated formulation and manufacturing solutions.

Higher-value opportunities

1. Sterile contract manufacturing: Manufacture and fill eptifibatide for generic suppliers or hospital-focused companies.
2. Ready-to-use bags: Reduce pharmacy preparation and support standardized catheterization-laboratory protocols.
3. Container-closure systems: Supply low-adsorption bags, syringes, elastomers, and validated infusion sets.
4. Analytical services: Characterize peptide impurities, particles, oxidation, and extractables.
5. Dual-source excipient qualification: Reduce supply interruptions for citric acid and packaging components.
6. Private-label hospital products: Use established injectable infrastructure to serve regional tenders.
7. Lifecycle extensions: Develop prefilled syringes or differentiated packaging where the commercial premium justifies added regulatory cost.

Revenue exposure

Direct revenue from the active ingredient is constrained by generic competition and acute-care purchasing. Revenue from excipients is smaller still. The most defensible margin pool is in sterile manufacturing, packaging, regulatory support, and dependable supply rather than in the buffer itself.

How strong is the patent estate for eptifibatide?

The patent estate is weak as a barrier to generic entry but potentially useful for narrow product improvements. Compound and original-use protection do not provide a durable commercial moat. A new entrant should not base its strategy on exclusivity pricing.

A stronger business case would combine:

• Low-cost peptide API sourcing.
• A validated, simple aqueous formulation.
• High-throughput sterile fill-finish.
• Two commercial strengths.
• Hospital-friendly packaging.
• Reliable distribution.
• A ready-to-use option for institutions willing to pay for workflow savings.

Key Takeaways

• Eptifibatide uses a simple aqueous formulation based on citric acid monohydrate, sodium hydroxide, and water for injection.
• The drug’s original U.S. exclusivity has expired, and no major active patent barrier defines the market.
• Excipient innovation alone is unlikely to support premium pricing.
• The highest-value opportunities are premixed infusion bags, prefilled bolus products, low-adsorption packaging, and sterile contract manufacturing.
• Peptide impurity control, particulate management, container compatibility, and supply continuity are the main technical risks.
• Generic competition is driven by FDA execution, manufacturing reliability, and hospital contracting rather than Paragraph IV litigation.
• Eptifibatide is not a biosimilar opportunity. It is a mature injectable peptide product with generic-drug economics.

FAQs

Can eptifibatide be formulated without citric acid?

A different buffer may be technically possible, but it would require new stability, compatibility, and regulatory support. Retaining the reference qualitative excipient profile is generally the lower-risk development strategy.

Is eptifibatide compatible with normal saline and dextrose?

The FDA label identifies compatibility with commonly used intravenous solutions, including 0.9% sodium chloride and 5% dextrose, subject to labeled conditions [1]. Compatibility should be confirmed for the specific bag, tubing, and administration system.

Does eptifibatide require refrigerated storage?

Storage requirements depend on the approved product and package configuration. Commercial developers must establish stability under labeled storage, shipping, and excursion conditions rather than assume that the liquid formulation has unrestricted room-temperature stability.

Can an eptifibatide manufacturer obtain new patents on a premixed bag?

A premixed bag may support patent claims if it includes a non-obvious formulation, container, stability profile, or manufacturing configuration. A conventional combination of the known drug, buffer, and standard infusion bag may provide limited patent strength.

Are eptifibatide shortages caused by excipient scarcity?

Shortages are more likely to arise from sterile manufacturing capacity, quality events, API availability, packaging components, or commercial exits than from scarcity of citric acid or sodium hydroxide. Packaging and fill-finish redundancy are more important risk controls.

References

1. U.S. Food and Drug Administration. (2019). Integrilin (eptifibatide) injection prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book.
3. U.S. Food and Drug Administration. (2025). Inactive ingredient database.
4. DailyMed. (2025). Eptifibatide injection product labeling. National Library of Medicine.
5. U.S. Pharmacopeia. (2024). General chapters for sterile products, particulate matter, and injectable pharmaceutical preparations. United States Pharmacopeial Convention.